CLSD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CLSD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Clearside Biomedical's Other Operating Expense for the three months ended in Sep. 2024 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.
Clearside Biomedical's quarterly Other Operating Expense stayed the same from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($0.00 Mil) but then increased from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil).
Clearside Biomedical's annual Other Operating Expense increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).
The historical data trend for Clearside Biomedical's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clearside Biomedical Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Other Operating Expense | Get a 7-Day Free Trial | - | - | - | - | - |
Clearside Biomedical Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Other Operating Expense | Get a 7-Day Free Trial | - | - | - | - | - |
GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Clearside Biomedical's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.
Benjamin R Yerxa | director | INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466 |
Bradford T Whitmore | 10 percent owner | 5215 OLD ORCHARD ROAD, SUITE 620, SKOKIE IL 60077 |
Charles A. Deignan | officer: Chief Financial Officer | C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005 |
George M Lasezkay | director | 1301 SECOND AVE., SUITE 4200, SEATTLE WA 98101 |
Nancy J Hutson | director | 64 MONTAUK AVENUE, STONINGTON CT 06378 |
Clay Thorp | director, 10 percent owner | C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701 |
Thomas Ciulla | officer: Chief Medical Officer | C/O CLEARSIDE BIOMEDICAL, INC., 900 NORTH POINT PARKWAY, SUITE 200, ALPHARETTA GA 30005 |
William D. Humphries | director | C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044 |
Jeffrey L Edwards | director | 2525 DUPONT DR, IRVINE CA 92612 |
Daniel H. White | director, officer: President and CEO | C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005 |
Gerald D. Cagle | director | 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921 |
Brion S. Raymond | officer: Chief Commercial Officer | C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005 |
Christy L Shaffer | director | INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466 |
Hatteras Venture Advisors Iv Sbic, Llc | 10 percent owner | 280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701 |
Hatteras Venture Advisors Iii, Llc | 10 percent owner | 280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701 |
From GuruFocus
By GuruFocus Research • 02-06-2024
By Marketwired • 06-12-2024
By Marketwired • 11-04-2024
By Marketwired • 08-27-2024
By GuruFocus Research • 03-12-2024
By GuruFocus News • 11-13-2024
By Marketwired • 05-09-2024
By Marketwired • 04-16-2024
By GuruFocus Research • 02-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.